Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

about

Role of BAX for outcome prediction in gastrointestinal malignancies.Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.

P2860

Q38108758-E8152816-6D34-4080-B1AD-8B756B694C51 Q38555225-D8895075-E253-4565-9BDD-BA74E77CBB6A

P2860

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

Item

http://www.wikidata.org/entity/Q44970937

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@en

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@nl

type

Item

label

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@en

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@nl

prefLabel

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@en

Lack of Bax expression is asso ...... ed colorectal cancer patients.

@nl

P1476

Lack of Bax expression is asso ...... ced colorectal cancer patients

@en

P2093

F Melotti

http://www.w3.org/2001/XMLSchema#string

G Bertarelli

http://www.w3.org/2001/XMLSchema#string

P Biondani

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer

Cancer statistics, 2009

Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.

P2888

s12094-012-0971-3

P304

582-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-012-0971-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23180349

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

about

P2860

P2860

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921